SSC
PCVX icon

Spruce Street Capital’s Vaxcyte PCVX Stock Holding History

Spruce Street Capital’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.8M Buy
306,047
+60,338
+25% +$3.28M 3.49% 9
2026
Q1 		$14.3M Sell
245,709
-154,651
-39% -$8.4M 3.43% 10
2025
Q4 		$18.5M Buy
+400,360
New +$17.9M 6.1% 5

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Spruce Street Capital's PCVX Position: Q2 2026 in Review

Spruce Street Capital increased its Vaxcyte (PCVX) stake by 25% in Q2 2026, buying an estimated $3.28M and bringing the position to 306,047 shares worth $17.8M. The position accounts for 3.49% of the portfolio, ranked #9.

Spruce Street Capital first reported a position in PCVX in Q4 2025 and has held it in 3 quarters since. The position peaked at $18.5M in Q4 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Spruce Street Capital held 306,047 shares of Vaxcyte worth $17.8M as of Q2 2026.
  • Spruce Street Capital bought 60,338 Vaxcyte shares in Q2 2026, an estimated $3.28M.
  • Vaxcyte made up 3.49% of Spruce Street Capital's portfolio in Q2 2026, its #9 holding.
  • Spruce Street Capital first reported a position in Vaxcyte in Q4 2025 and has held it in 3 quarters since.
  • Spruce Street Capital's Vaxcyte position peaked at $18.5M in Q4 2025.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Spruce Street Capital's 13F filing for Q2 2026, filed 13 Aug 2026.